Mike Hollan

The company plans to spend the coming years strengthening its market position and pipeline while also clearing its issues with litigation and debt.

Heavey discusses how the industry can avoid having efforts to accelerate discovery and development be hampered by manufacturing concerns.

Rus discusses his company’s work with neuroplastogens and how they differ from similar, psychedelic treatments.

The partnership has the goal of improving patient education and treatment directions.

The paper discusses multiple steps the industry can take to ensure that patients have access to these treatments.

Stark discusses how the ways that data is reshaping commercial strategies.

Simon discusses a recent survey ICON conducted with professionals in obesity-related clinical research.

The agency updated its recommendations after a vote by the ACIP advisory committee.

The agency teamed up with the software company to develop platforms and networks to collect de-identified data.

The device can detect potential warning signs of serious conditions.

The medication already has a black box warning on it, but the AG’s office believes stricter actions should be taken.

FDA has approved the medication in adults and children with allergies.

The site will have a staff of 400 employees.

The agency issued a statement reminding the public that it has not approved any such devices for this use.

The gallery will be a part of the HLTH Europe event and will be open to all attendees.

The Gilead Sciences CEO will be joined by new board members from Pfizer and Sanofi.

Kaufman discusses the ways the digital biomarkers are improving Alzheimer’s research by directly tackling some of the unique challenges that researchers face.

Papa will take over the over effective immediately.

The previous CEO, Richard A. Gonzalez, has served as CEO since 2013.

Anderson discusses the complexities of planning for a global launch and the common mistakes companies make that cause problems along the way.

Wong discusses trends regarding M&A and how he expects this to continue and change in the coming months.

Lightburn discusses his company’s work with psychedelics and the unique business strategies required for these treatments.

Iris Kuss, head of clinical development, and Jorge Ortiz, head of medical affairs, discuss the company’s recent presentation at ASCO GU.

This acquisition will add asthma treatment A1O-001 to GSK’s portfolio.

Its path and application could model the same road as AI.

Harpreet Gill, vice president of real-world solutions - project management at ICON, discussesthe progress and challenges in advancing data-driven tools and approaches in decentralized clinical trials, where ongoing education remains paramount.

Bruce Phelan of Blue Fin discusses pharma’s need for access to manufacturing sites.

A new survey of pharma executives suggests that many are fully embracing the use of AI and are making financials plans based on the technology’s usage.

BioNTech will invest $200 million and get access to Autolus’ manufacturing sites.

According to the study conducted by Technavio, North America will contribute to 37% of the expected growth.